Preparing for Cell and Gene Therapy Logistics: Anovo’s Infrastructure Development
April 12, 2025
As cell and gene therapies move from clinical trials toward commercial markets, Anovo is strategically preparing the infrastructure to support these revolutionary treatments when they become available. Our preparation combines 15+ years of rare disease expertise with planned investments in advanced therapy capabilities.
Current Temperature Management Foundation
Multi-Zone Storage Systems
Standard refrigerated storage (2-8°C) with 24/7 monitoring
Freezer storage at -20°C
Real-time monitoring with immediate alert protocols
Temperature-controlled shipping containers for secure transport
Cold-Chain Infrastructure
Anovo currently maintains comprehensive cold-chain infrastructure including specialized packaging systems, validated storage capabilities, and direct control over the cold-chain process from storage through patient delivery for traditional rare disease therapies.
The Anovo Advantage for Future Advanced Therapies
Single-Vendor Integration Model
Our proven approach of eliminating handoff points through direct coordination between patient services and logistics and unified quality management positions us well for the complex requirements of advanced therapies.
Proven Rare Disease Foundation
Our future advanced therapy capabilities will build on our established rare disease expertise, treatment center relationships, high-value therapy experience, and regulatory compliance track record.
Preparing for Tomorrow’s Treatments
Today, Anovo successfully manages complex rare disease therapies within standard cold-chain requirements using specialized handling protocols and enhanced quality systems. As the cell and gene therapy market develops, our roadmap includes strategic infrastructure investments and expanded technology capabilities to meet the unique demands of these advanced treatments. These planned enhancements include specialized temperature monitoring systems and validated packaging solutions designed specifically for gene and cell therapy requirements.
Interested in discussing how Anovo is preparing for advanced therapy logistics? Contact us to learn about our development roadmap and readiness for next-generation treatments.
Related Posts
Nationwide Coverage: Anovo Geographic Reach and Service Consistency
True nationwide specialty pharmacy coverage requires comprehensive infrastructure, robust logistics partnerships, and operational systems designed to overcome geographic challenges. At…
October 24, 2025
Business Continuity Planning: Anovo’s Redundancy and Disaster Recovery
When patients depend on life-changing rare disease therapies, service interruptions can have devastating health consequences. At Anovo, our business continuity…
September 8, 2025
Behind the Delivery: How Anovo’s 3PL/Wholesale Team Keeps Rare Therapies Moving
At Anovo, every team plays a role in delivering hope to patients living with rare diseases. While many think of…
August 20, 2025